Research on Time-based Enterprise Competitive strategy and It's Applications

AbstractAbout the competitive advantage, academe and entrepreneur are always studying and discussing this question. Different persons have different opinions, some people think product quality and price are the competitive advantages of enterprise, and others think service, famous brand and innovation are. In this paper, I will discuss this question in other means. I think time is also the competi...学位：工商管理硕士院系专业：管理学院工商管理教育中心_工商管理硕士(MBA)学号：20011502

可控降解抗感染材料的体外释药机制研究

在前期合成并表征了可控降解抗感染材料环丙沙星聚氨酯(CFPU)的基础上,建立高效液相色谱法(HPLC)测定其体外降解释放抗菌药物环丙沙星的含量;通过制作累积药物释放曲线,考察不同降解介质及其浓度对药物释放的影响;并对累积药物释放曲线进行拟合,研究其体外可控降解的药物释放机制。结果表明建立的HPLC法简单准确可靠。该材料的降解具有生物响应性,且符合一级动力学;药物释放是以Ritger-Pappas方程(0.45<n<0.89)即扩散与骨架溶蚀相结合的机制进行,在无炎症时以扩散为主,而炎症发生时反之,且炎症越严重,骨架溶蚀越占优势

咸水膜下滴灌对棉花品质和产量的影响

在相同灌溉水量条件下,以不同比例混合塔里木盆地干旱区矿化度为3.56g/L的地下咸水和矿化度为0.4g/L的地表淡水,设置6种处理,采用膜下滴灌技术充分灌溉新陆早13号棉花,探求土壤水盐的动态变化规律和咸水灌溉对棉花品质与产量的影响。结果表明:在整个灌溉期,不同咸水灌溉0～20cm表层土壤的含盐量变化最大,0～50cm次之,0～100cm最小;非灌水期土壤含盐量随着体积含水量的减少而增加,灌水期土壤含盐量随着灌水量和灌水次数的增加而显著减少;咸水灌溉虽然使单株铃数减少、棉花减产,但对棉花衣分和单铃重没有影响

微咸水膜下滴灌条件下棉花耗水规律的研究

在相同灌溉水量条件下,以不同比例混合塔里木盆地干旱区地下咸水(3.56 g/L)和地表淡水(0.4 g/L),采用膜下滴灌技术充分灌溉,探求棉花在微咸水膜下滴灌条件下的耗水规律。经研究表明以处理3的矿化度为分界线,表现出棉花耗水规律受水盐协迫不同因素的影响

Criterion of aerodynamic performance of large-scale offshore horizontal axis wind turbines

以近海风能工程为研究目标,对具有不同特性参数(设计风速、叶尖线速度和转轮实度)的大容量(1~10 MW)风力机转轮的气动性能与几何特性进行分析与研究.首先提出大型机组转轮气动性能优化判据:在其直径最小的前提下具有尽可能高的年可用风能特性因数以及与之相关的风能利用系数,因而可捕获最多风能,使年发电量最大.接着给出影响它的几个主要气动参数,如转轮设计风速、叶尖线速度以及转轮实度,并分析风力机在近海气象条件下运转时上述两个气动指标随这些参数变化的规律.提供的气动分析方法及结果可作为大型近海风力机转轮气动性能的评价基础

失重飞机搭载气／液两相流实验研究

利用俄罗期ＩＬ－７６ＭＤＫ失重飞机对失重条件下方形截面（１２ｍｍ×１２ｍｍ）管道内气／液两相流动进行了实验研究，观测到失重条件下气／液两相泡状流、弹状流和环状流等三种主要流型，同时得到了气、液两相介质的流量、温度和实验段内压力等结果，分析了失重条件下方形截面管道内气／液两相流型转换的条件

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials